SCHEMBL3266258

SCHEMBL3266258

NC(=O)COC(=O)NC1CCN(c2ccc(Br)cn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.43
KMT2A Q03164 1/20 0.42
AKR1C3 P42330 1/20 0.42
HPGDS O60760 4/20 0.40
CKS1B P61024 2/20 0.40
SKP1 P63208 2/20 0.40
SKP2 Q13309 2/20 0.40
USP30 Q70CQ3 3/20 0.40
PANK3 Q9H999 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ABL1 P00519 1/20 0.39
LMNA P02545 1/20 0.39
TDO2 P48775 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PAK1 Q13153 1/20 0.39
SMO Q99835 1/20 0.39
PDE10A Q9Y233 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269155 0.85 CHIT1 (0.42) KMT2AAKR1C3CKS1BSKP1SKP2
SCHEMBL3266914 0.84 CKS1B (0.49) HRH3CKS1BSKP1SKP2USP30
SCHEMBL3269077 0.83 CHRM4 (0.49) KMT2AAKR1C3KDM4EABL1LMNA
SCHEMBL3265677 0.83 TDO2 (0.51) HRH3HPGDSCKS1BSKP1SKP2
SCHEMBL31140036 0.83 ALDH1A1 (0.53) KMT2ACKS1BSKP1SKP2
SCHEMBL29197825 0.83 ALDH1A1 (0.53) KMT2ACKS1BSKP1SKP2
SCHEMBL3268988 0.80 HSD11B1 (0.41) KMT2ACKS1BSKP1SKP2USP30
SCHEMBL3025692 0.80 CKS1B (0.60) AKR1C3CKS1BSKP1SKP2PANK3
SCHEMBL1728874 0.80 AKR1C3 (0.50) HRH3AKR1C3HPGDSCKS1BSKP1
SCHEMBL31140038 0.80 AKR1C3 (0.50) HRH3AKR1C3HPGDSCKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HRH3 33/4885KMT2A 2458/4885AKR1C3 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.